AAIC 2020: Phase II clinically confirmed that recombinant GM-CSF has therapeutic potential for Alzheimer's disease.

A study presented at the 2020 International Conference of the Alzheimer's Society (AAIC) showed that recombinant human granulocyte-macrophage cluster stimulation factor (GM-CSF) Sargramostim showed potential for the treatment of Alzheimer's disease.
: Results of the Phase 2 double-blind trial showed that patients who received daily subderrical injections of sargramostim 250 mcg/m2 had an average minimum mental state test (MMSE) score that improved compared to the baseline level (P .0074).
who used sargramostim in random groups also had an improved MMSE score compared to those who used placebos in random groups (P .037).
compared to placebos, sargramostim's improvement in MMSE was maintained during the first follow-up on the 45th day after treatment (P .0272).
and imaging analysis showed serious drug-free adverse events, including imaging abnormalities associated with amyloid proteins.
the patients in the study were between 55 and 85 years of age (n s 40), had mild to moderate Alzheimer's disease (MMSE, 10-26), and received stable treatment (cholinesterase inhibitors/meth) for at least 2 months.
, M.D., at the University of Colorado's Alzheimer's Awareness Center, conducted a retrospective analysis of cognitive studies of cancer patients treated with hematogenic cell transplantation.
in patients who received a set of stimulation factors that stimulated the recovery of immune system function, the researchers found significant improvements in cognitive function in patients who received sargramostim combined with non-gestation compared to those who received non-gestim alone.
these findings suggest that sargramostim may well be a new treatment for reversing amyloid disease and cognitive impairment in the brain," the authors said.
"